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ABSTRACT 
Objective: To develop and validate two simple and cost effective spectrophotometric methods for the determination of Ornidazole (OND) in pure 
form and in pharmaceutical tablet dosage form. 
Methods: Single point standardization method was used for quantitative estimation of OND. In method 1 absorbance was measured at 311 nm (λmax 
of OND in methanol) using methanol as a solvent system and in method 2 absorbance was measured at 277 nm (λmax
Results: The two methods obeyed Beer’s law in the concentration range of 3-18 µg/ml (methanol) and 10-35 µg/ml (0.1 N HCl) respectively. The 
methods were validated for parameters such as linearity, accuracy, and precision, limit of detection (LOD), limit of quantification (LOQ), robustness 
and ruggedness as per ICH guidelines. 
 of OND in 0.1 N HCl) using 0.1 
N HCl as the solvent system. 
Conclusion: The developed methods were used for determining the content of OND in commercial tablets. The proposed methods were thus found 
to be suitable for quantitative estimation of OND in bulk and tablet formulation without any interference of the excipients and can be employed for 
quality control of Ornidazole in tablet dosage form. 
Keywords: Ornidazole, Validation, Single point standardization, ICH guidelines 
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INTRODUCTION 
Ornidazole (OND), a 5-nitroimidazole is used in the treatment of 
protozoal infections and also in the treatment and prophylaxis of 
anaerobic infections. It has been investigated for use in Crohn's 
disease after bowel resection. OND is converted into reduction 
products that interact with DNA to cause the destruction of the 
helical DNA structure and strand leading to inhibition of protein 
synthesis causing cell death in susceptible organisms. Chemically, it 
is 1-chloro-3-(2-methyl-5-nitro-1 H-imidazol-1-yl propan-2-ol and 
its structure is shown in fig. 1. It is used either as monotherapy or in 
combination with cephalosporins and in fluoroquinolone antibiotics 
[1-6]. OND is not official in any Pharmacopoeia. 
The methods that have already been reported for estimation of OND in 
bulk and in the formulation are UV-Spectrophotometry, RP-HPLC and 
HPTLC. UV-Spectrophotometric methods have been reported using 
ethanol and distilled water as a solvent for estimation of OND alone [7, 
8]. OND in its various drug combinations have been estimated using 
UV-Spectrophotometry [9-16], RP-HPLC [17, 18] and HPTLC [18, 
19]. To the best of our knowledge, the quantitative estimation of 
OND alone in methanol and 0.1 N HCl by zero order UV-
Spectrophotometry has not been reported yet. Thus, an attempt was 
made to develop two simple, accurate and precise zero order UV-
Spectroscopic methods for determination of OND using methanol 
and 0.1 N HCl as the solvent system at its respective λmax values. 
 
Fig. 1: It shows chemical structure of Ornidazole [3] 
 
MATERIALS AND METHODS 
Spectrophotometric measurements were done using a double beam 
LABINDIA 3000+
Preparation of stock solution 
UV/Visible spectrophotometer and a pair of 1 cm 
matched quartz cells was used. All samples were weighed on 
Shimadzu digital balance (Model No. AUY220). All chemicals and 
reagents were of analytical grade. OND was obtained as a gift sample 
from Nicholas Piramal, Ltd; Goregaon, Mumbai. It was authenticated 
before use by performing identification tests. Owing to the good 
solubility of OND in methanol and 0.1 N HCl, these two solvents were 
chosen to dissolve the drugs. 
Method 1 
A quantity of 25 mg of OND was accurately weighed and dissolved in 
25 ml methanol to get a solution containing 1 mg/ml of OND. 
Method 2 
Similarly, a stock solution having a concentration of OND as 1 mg/ml 
was prepared by dissolving 25 mg drug in 0.1 N HCl and making up 
the volume to 25 ml with the same solvent. 
Preparation of linearity solutions 
The stock solutions of OND in methanol and 0.1 N HCl were serially 
diluted to obtain solutions ranging from 3-18 µg/ml (methanol) and 
10-35 µg/ml (0.1 N HCl) respectively. 
Determination of wavelength 
A solution of a suitable concentration of OND in methanol and 0.1 N 
HCl was scanned in UV range from 200-400 nm to determine the 
wavelength of maximum absorption. For linearity determination, 
validation studies and assay of OND in the marketed formulation, 
absorbance measurements were carried out at 311 nm and 277 nm 
using methanol and 0.1 N HCl respectively. The zero order UV 
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spectrum of OND in methanol and 0.1 N HCl was recorded. In order 
to confirm the λmax, first order spectrum was recorded for both the 
methods. The zero crossing points were observed at 262 and 311 
nm (methanol) and 241 and 277 nm (0.1 N HCl). 
Calibration curve 
Method 1 
From the stock solution of OND (1 mg/ml), 1 ml was pipetted out 
and transferred to 10 ml volumetric flask. The volume was made up 
with methanol. From this solution (100 µg/ml), various linearity 
solutions were prepared ranging from 3-18 µg/ml by pipetting out 
0.3, 0.6, 0.9, 1.2, 1.5, 1.8 ml respectively into 10 ml volumetric flasks 
and volume was made up to 10 ml using the same solvent. 
Method 2 
Similarly from the stock solution of OND (1 mg/ml), 5 ml was 
pipetted out and transferred to 50 ml volumetric flask. The volume 
was made up with 0.1 N HCl. From this solution (100 µg/ml), various 
linearity solutions were prepared ranging from 10-35 µg/ml by 
pipetting out 1, 1.5, 2, 2.5, 3, 3.5 ml respectively into 10 ml 
volumetric flasks and volume was made using the same solvent. 
The calibration curves were generated. The zero order and first 
order spectra of linearity solutions for the two proposed methods 
were recorded. 
Assay of Ornidazole in bulk and in tablet dosage form 
The assay of Ornidazole in bulk was carried out by accurately 
weighing and transferring a quantity of 25 mg of the drug to two 
separate 25 ml volumetric flask and making up the volume with 
methanol and 0.1 N HCl. The solutions were suitably diluted, and 
their absorbance was recorded at 311 nm (λmax of OND in methanol) 
and 277 nm (λmax
The assay of OND tablets (ORNI 500; manufactured by Zydus 
Healthcare, Sikkim) was carried out by determining the average 
weight of 20 tablets. The tablets were then ground to fine powder 
and mixed thoroughly. A quantity of 33 mg of tablet powder 
equivalent to 25 mg of OND was accurately weighed and transferred 
to two separate 25 ml volumetric flasks. After adding the respective 
solvents, the solutions were sonicated for 20 min to extract the drug 
completely in methanol and 0.1 N HCl. The volume was made up 
with the same solvents. The solutions were filtered through 
Whatman filter paper no. 41 and were suitably diluted. The 
absorbance of solutions was measured at their respective λ




against the solvent as blank. 
The proposed methods were evaluated for various validation 
parameters as per ICH guidelines [20]. Intra-day and inter-day 
precision were determined at three different time intervals on same 
and different days by analyzing the drug solution having 
concentration 15 µg/ml (methanol) and concentration 20 µg/ml (0.1 
N HCl). The % RSD was calculated. The accuracy of the method was 
evaluated by carrying out recovery experiments at three levels, and 
percentage recovery was determined. Limit of detection (LOD) and 
Limit of quantification (LOQ) was calculated from calibration curves 
using the respective slope and standard deviation of y-intercepts. 
RESULTS 
The UV scans of OND in methanol and 0.1 N HCl are shown in fig. 2 
and 3 respectively. Similarly, the first order spectra of both the 
methods are shown in fig. 4 and 5. The calibration curves are shown 
in fig. 6 and 7. Zero and first order overlay spectra of linearity 
solutions of OND were constructed in methanol and were shown in 
fig. 8 and 9 respectively. Similarly, fig. 10 and 11 show zero and first 
order spectra of linearity solutions of OND in 0.1 N HCl respectively. 
The results of regression analysis for quantification of OND in 
methanol and 0.1 N HCl is shown in table 1.  
The accuracy and recovery studies were carried out on tablet 
formulation for both the methods and the results are shown in table 2 
and 3 respectively. The results of reproducibility, intra-day precision and 
inter-day precision are shown in table 4, 5 and 6 respectively. 
Robustness of the methods was determined by carrying out the analysis 
under different operating conditions such as wavelength and variation in 
concentrations. The respective absorbance was noted, and the result was 
expressed as % RSD as shown in table 7. The ruggedness of the methods 
was also determined by carrying out the analysis by different analyst and 
the respective absorbance of the solution of OND having concentration 
as 15μg/ml for method 1 and 20µg/ml for method 2 were noted. The 
results are shown in table 8. The result of the assay of OND on the tablet 
dosage form is shown in table 9. 
 
Table 1: It shows regression analysis of Ornidazole in methanol and 0.1 N HCl 
Parameters  Method 1 Method 2 
Solvent  Methanol  0.1 N HCl 
Linearity range (µg/ml) 3-18 µg/ml 10-35 µg/ml 
Wavelength, λmax 311  (nm) 277 
Regression equation y=0.035x+0.001 y=0.028x+0.010 
Correlation coefficient (r2 0.999 ) 0.999 
Molar absorptivity, ε (L/mol/cm) 8873 6391 
Sandell’s sensitivity (µg. cm2 0.025 /0.001 absorbance unit) 0.034 
y-intercept 0.001 0.010 
95% confidence interval for slope 1.25354 × 10 1.25354 × 10-5 
95% confidence interval for intercept 
-5 




LOQ (µg/ml) 0.041 2.53 
 
 
Fig. 2: It shows UV spectrum of Ornidazole in methanol 
 
Fig. 3: It shows UV spectrum of Ornidazole in 0.1 N HCL 
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Fig. 4: It shows first order spectrum of OND in methanol 
 
 
Fig. 5: It shows first order spectrum of OND in 0.1 N HCl 
 
 
Fig. 6: It shows calibration curve of Ornidazole in methanol 
 
 
Fig. 7: It shows calibration curve of Ornidazole in 0.1 N HCl 
 
 
Fig. 8: It shows overlain zero-order spectrum of linearity solutions of OND in methanol 
 
 
Fig. 9: It shows overlain first order spectrum of linearity solutions of OND in methanol 
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Fig. 10: It shows overlain zero-order spectrum of linearity solutions of OND in 0.1N HCl 
 
 
Fig. 11: It shows overlain first order spectrum of linearity solutions of OND in 0.1 N HCl 
 
Table 2: It shows results of accuracy studies for method 1 and 2 
Recovery level Sample concentration (µg/ml) % Recovery* %RSD (average of three determinations±SD) SE 
Method 1 80% 12 100.6±0.7286 0.725 0.420 
100% 15 103.2±0.380 0.370 0.220 
120% 18 101.8±0.410 0.403 0.237 
Method 2 80% 16 98.2±1.175 1.196 0.680 
100% 20 98.6±1.013 1.028 0.585 
120% 24 99.4±1.379 1.390 0.796 
t-calculated value: 0.01034; F-calculated value: 0.910923, t-tabulated value (P = 0.05): 2.132; F-tabulated value (P = 0.05, df1= 2, df2= 2): 19.00, 
*mean of three determinations at each level, P= level of significance, SD= Standard deviation (n= 3), RSD= Relative standard deviation, SE= Standard 
error (n= 3), df1 and df2
 
= degrees of freedom for method 1 and method 2 respectively. 





Amount of drug in 








Method 1 80 25 16 100.73±1.545 1.530 0.890 
 100 25 20 101.75±1.190 1.170 0.690 
 120 25 24 100.01±1.169 0.220 0.645 
Method 2 80 25 16 99.91±0.336 0.337 0.190 
 100 25 20 96.12±0.095 0.099 0.055 
 120 25 24 97.9±0.129 0.132 0.074 
 
Table 4: It shows results of reproducibility studies for method 1 and 2 
Observations  Method 1 Method 2 
Concentration  15µg/ml 20µg/ml 
Wavelength  311 nm 277 nm 
Absorbance  0.657 0.563 
Mean (average of 9 determinations) 0.670 0.559 
SD 0.014 0.004 
%RSD 0.521 0.747 
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Table 5: It shows results of intra-day precision for method 1 and 2 
Time  %RSD 
Method 1  Method 2 
10.00 am 0.463 0.330 
1.00 pm 0.532 0.665 
4.00 pm 0.611 0.480 
Average %RSD 0.535 0.490 
 
Table 6: It shows results of inter-day precision for method 1 and 2 
Day  %RSD 
Method 1 Method 2 
Day 1 0.571 0.890 
Day 2 0.655 0.787 
Day 3 0.460 1.360 
Average %RSD 0.562 1.011 
 
Table 7: It shows results of robustness for method 1 and 2 
Method  Wavelength (nm) Concentration (µg/ml) Absorbance (mean of three determinations) (n = 3) % RSD 
Method 1 309 12 0.428 0.467 
15 0.539 0.283 
18 0.642 0.412 
311 12 0.431 0.837 
15 0.542 0.384 
18 0.644 0.237 
313 12 0.428 0.713 
15 0.537 0.468 
18 0.642 0.311 
Method 2 275 16 0.455 1.249 
20 0.564 0.569 
24 0.686 1.27 
277 16 0.458 1.240 
20 0.568 0.530 
24 0.690 1.380 
280 16 0.454 1.100 
20 0.563 0.542 
24 0.684 1.270 
 
Table 8: It shows results of ruggedness for method 1 and 2 
Method  Observations  Analyst 1 Analyst 2 
Method 1 Absorbance  0.542 0.538 
Mean, n= 6 
(average of 6 determinations) 
0.546 0.538 
SD 0.0035 0.002 
% RSD 0.643 0.371 
Method 2 Absorbance  0.560 0.560 
Mean, n= 6 
(average of 6 determinations) 
0.562 0.563 
SD 0.0020 0.0030 
% RSD 0.373 0.539 
 
Table 9: It shows results of assay of marketed formulation of OND (ORNI 500) 
Tablet formulation (ORNI 500) Label claim 
(mg/tab) 
% label claim (average of three 
determinations±SD) 
% RSD SE 
Method 1 (Solvent: Methanol) 500 99.75±0.515 0.517 0.297 
Method 2 (Solvent: 0.1 N HCl) 500 96.67±0.362 0.375 0.375 
t-calculated value: 0.0203; F-calculated value: 0.159, t-tabulated value (P = 0.05): 1.812; F-tabulated value (P = 0.05, df1= 2, df2
 
= 2): 19.00 
DISCUSSION 
The present study involved the development and validation of a UV-
Spectrophotometric method for analysis of OND in methanol and 0.1 
N HCl. The λmax of OND was observed to be 311 nm and 277 nm in 
methanol and 0.1 N HCl respectively. The drug was found to be 
soluble and stable in both the solvents. The proposed methods 
obeyed Beer’s law in the concentration ranging from 3-18 µg/ml and 
10-35 µg/ml respectively. The LOD and LOQ for method 1 were 
obtained as 0.019 µg/ml and 0.041 µg/ml, respectively, and for 
method 2; it was obtained as 0.836 µg/ml and 2.53 µg/ml, 
respectively. The % RSD values of recovery and precision 
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experiments were within limits for both the methods indicating high 
accuracy and precision of the methods. The % recovery values were 
obtained as 101.75 and 96.12 for method 1 and 2 respectively. The 
methods were also found to be unaffected by minor changes in 
operating conditions of analysis such as wavelength and 
concentration. The methods were found to be specific, and no 
interference from sample matrix was observed as shown by high 
percent recovery values. The ruggedness of the methods was also 
established as the % RSD values obtained between two sets of data 
by different analysts was found to be well within limits. The assay 
results on marketed formulation obtained by the proposed methods 
were statistically evaluated and compared by using tests of 
significance such as Students t-test and F-test. No significant 
difference was found to exist between the two proposed methods. 
CONCLUSION 
The present study enabled two simple, rapid, precise and accurate 
quantitative methods for analysis of OND in bulk and commercial 
formulations. No tedious extraction procedures or extensive 
treatment of samples is required, which allows for greater ease of 
application of the method. The statistical comparison of the methods 
showed that the two methods are not significantly different. Hence, 
the methods can be applied to quality control of OND in bulk as well 
as in its dosage forms. 
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